⚠ Novel chemotype — no close known analogue (best Tanimoto < 0.3). Unexplored chemical space relative to ChEMBL.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL21244808 | 0.92 | — | — | |
| SCHEMBL21244765 | 0.88 | — | — | |
| SCHEMBL20023964 | 0.84 | MBOAT4 (0.32) | — | |
| SCHEMBL21244549 | 0.84 | — | — | |
| SCHEMBL21245074 | 0.82 | — | — | |
| SCHEMBL20029456 | 0.78 | SCN9A (0.33) | — | |
| Hydrochloric Acid SCHEMBL29139239 | 0.77 | SCN9A (0.32) | — | |
| SCHEMBL21244790 | 0.77 | — | — | |
| SCHEMBL20029465 | 0.76 | — | — | |
| SCHEMBL20023917 | 0.76 | LNPEP (0.31) | — |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 63 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20260125363-A1 | PROCESSES FOR MAKING MODULATORS OF CYSTIC FIBROSIS TRANSMEMBRANE CONDUCTANCE REGULATOR | VERTEX PHARMA (US) | 2026-05-07 | — | — | US | disclosed |
| US-12415798-B2 | Processes for making modulators of cystic fibrosis transmembrane conductance regulator | VERTEX PHARMACEUTICALS INCORPORATED (US) | 2025-09-16 | — | — | US | disclosed |
| US-20250171469-A1 | MODULATORS OF CYSTIC FIBROSIS TRANSMEMBRANE CONDUCTANCE REGULATOR | VERTEX PHARMA (US) | 2025-05-29 | — | — | US | disclosed |
| CN-117843619-A | Modulators of cystic fibrosis transmembrane conductance regulator, pharmaceutical compositions, methods of treatment, and methods for preparing the modulators | 弗特克斯药品有限公司 | 2024-04-09 | — | — | CN | disclosed |
| CN-111757874-B | Methods for preparing modulators of cystic fibrosis transmembrane conductance regulator | 弗特克斯药品有限公司 | 2024-03-08 | — | — | CN | disclosed |
| US-20240025877-A1 | PROCESSES FOR MAKING MODULATORS OF CYSTIC FIBROSIS TRANSMEMBRANE CONDUCTANCE REGULATOR | VERTEX PHARMACEUTICALS INCORPORATED | 2024-01-25 | — | — | US | disclosed |
| US-20240025877-A1 | PROCESSES FOR MAKING MODULATORS OF CYSTIC FIBROSIS TRANSMEMBRANE CONDUCTANCE REGULATOR | VERTEX PHARMACEUTICALS INCORPORATED | 2024-01-25 | — | — | US | disclosed |
| US-20240025877-A1 | PROCESSES FOR MAKING MODULATORS OF CYSTIC FIBROSIS TRANSMEMBRANE CONDUCTANCE REGULATOR | VERTEX PHARMACEUTICALS INCORPORATED | 2024-01-25 | — | — | US | disclosed |
| CN-110267948-B | Modulators of cystic fibrosis transmembrane conductance regulator, pharmaceutical compositions, methods of treatment, and methods for preparing the modulators | 弗特克斯药品有限公司 | 2023-12-08 | — | — | CN | disclosed |
| US-20230357191-A1 | MODULATOR OF THE CYSTIC FIBROSIS TRANSMEMBRANE CONDUCTANCE REGULATOR, PHARMACEUTICAL COMPOSITIONS, METHODS OF TREATMENT, AND PROCESS FOR MAKING THE MODULATOR | VERTEX PHARMACEUTICALS (SAN DIEGO) LLC | 2023-11-09 | — | — | US | disclosed |
| WO-2019113476-A2 | PROCESSES FOR MAKING MODULATORS OF CYSTIC FIBROSIS TRANSMEMBRANE CONDUCTANCE REGULATOR | VERTEX PHARMACEUTICALS INCORPORATED (US) | 2019-06-13 | — | — | WO | disclosed |
| WO-2019113476-A2 | PROCESSES FOR MAKING MODULATORS OF CYSTIC FIBROSIS TRANSMEMBRANE CONDUCTANCE REGULATOR | VERTEX PHARMACEUTICALS INCORPORATED (US) | 2019-06-13 | — | — | WO | disclosed |
| WO-2019079760-A1 | CRYSTALLINE FORMS AND COMPOSITIONS OF CFTR MODULATORS | VERTEX PHARMACEUTICALS INCORPORATED (US) | 2019-04-25 | — | — | WO | disclosed |
| US-20190119253-A1 | CRYSTALLINE FORMS AND COMPOSITIONS OF CFTR MODULATORS | VERTEX PHARAMCEUTICALS INCORPORATED (US) | 2019-04-25 | — | — | US | disclosed |
| US-20180162839-A1 | Modulator of the Cystic Fibrosis Transmembrane Conductance Regulator, Pharmaceutical Compositions, Methods of Treatment, and Process for Making the Modulator | VERTEX PHARMACEUTICALS (SAN DIEGO) LLC | 2018-06-14 | — | — | US | disclosed |
| WO-2018107100-A1 | MODULATOR OF CYSTIC FIBROSIS TRANSMEMBRANE CONDUCTANCE REGULATOR, PHARMACEUTICAL COMPOSITIONS, METHODS OF TREATMENT, AND PROCESS FOR MAKING THE MODULATOR | VERTEX PHARMACEUTICALS INCORPORATED (US) | 2018-06-14 | — | — | WO | disclosed |
| US-20180162839-A1 | Modulator of the Cystic Fibrosis Transmembrane Conductance Regulator, Pharmaceutical Compositions, Methods of Treatment, and Process for Making the Modulator | VERTEX PHARMACEUTICALS (SAN DIEGO) LLC | 2018-06-14 | — | — | US | disclosed |
| WO-2018064632-A1 | MODULATOR OF CYSTIC FIBROSIS TRANSMEMBRANE CONDUCTANCE REGULATOR, PHARMACEUTICAL COMPOSITIONS, METHODS OF TREATMENT, AND PROCESS FOR MAKING THE MODULATOR | VERTEX PHARMACEUTICALS INCORPORATED (US) | 2018-04-05 | — | — | WO | disclosed |
| US-20180093969-A1 | Modulator of Cystic Fibrosis Transmembrane Conductance Regulator, Pharmaceutical Compositions, Methods of Treatment, and Process for Making the Modulator | VERTEX PHARMACEUTICALS INCORPORATED | 2018-04-05 | — | — | US | disclosed |
| US-20180093969-A1 | Modulator of Cystic Fibrosis Transmembrane Conductance Regulator, Pharmaceutical Compositions, Methods of Treatment, and Process for Making the Modulator | VERTEX PHARMACEUTICALS INCORPORATED | 2018-04-05 | — | — | US | disclosed |